PubRank

Milton L Brown

Author PubWeight™ 64.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009 2.17
2 High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 2010 1.54
3 VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther 2010 1.49
4 AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009 1.48
5 Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol 2007 1.44
6 Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin Prostate Cancer 2003 1.44
7 Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev 2006 1.34
8 Predicting new indications for approved drugs using a proteochemometric method. J Med Chem 2012 1.29
9 Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem 2012 1.25
10 Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther 2009 1.24
11 Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berl) 2010 1.20
12 STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A 2013 1.20
13 Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg Med Chem 2004 1.13
14 Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol 2009 1.13
15 Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol 2005 1.07
16 YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 2011 1.07
17 Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. Mol Cancer Ther 2003 1.06
18 Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole. Mol Pharmacol 2007 1.04
19 Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 2012 1.04
20 Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) 2011 1.02
21 Asymmetric synthesis of 2,3-dihydro-2-arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity. J Med Chem 2008 1.02
22 Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats. Psychopharmacology (Berl) 2012 1.00
23 Synthesis and evaluation of hermitamides A and B as human voltage-gated sodium channel blockers. Bioorg Med Chem 2011 0.97
24 DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci U S A 2013 0.96
25 Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther 2008 0.96
26 Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem 2007 0.95
27 Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget 2013 0.94
28 Small molecule inducers of angiogenesis for tissue engineering. Tissue Eng 2006 0.92
29 A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacology 2006 0.92
30 Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem 2011 0.90
31 Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore. Bioorg Med Chem 2008 0.89
32 Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats. J Med Chem 2013 0.88
33 Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft. J Med Chem 2010 0.87
34 VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther 2011 0.86
35 Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem 2003 0.86
36 Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget 2014 0.85
37 Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol Cancer Ther 2011 0.85
38 Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands. J Med Chem 2013 0.84
39 Expansion of microvascular networks in vivo by phthalimide neovascular factor 1 (PNF1). Biomaterials 2008 0.84
40 Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2. Bioorg Med Chem 2006 0.84
41 Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer. Bioorg Med Chem 2004 0.84
42 Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6. J Med Chem 2014 0.83
43 Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools. Tissue Eng 2007 0.83
44 A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem 2009 0.83
45 Synthesis of C-glycoside analogues of beta-galactosamine-(1-->4)-3-O-methyl-D-chiro-inositol and assay as activator of protein phosphatases PDHP and PP2Calpha. Bioorg Med Chem 2010 0.83
46 Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clin Prostate Cancer 2004 0.82
47 Facile synthesis of an azido-labeled thalidomide analogue. Org Lett 2003 0.82
48 Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci 2004 0.81
49 Design, synthesis, and development of novel caprolactam anticonvulsants. Bioorg Med Chem 2003 0.81
50 Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule. Bioinformatics 2008 0.81
51 Human genome search in celiac disease: mutated gliadin T-cell-like epitope in two human proteins promotes T-cell activation. J Mol Biol 2002 0.80
52 Phthalimide neovascular factor 1 (PNF1) modulates MT1-MMP activity in human microvascular endothelial cells. Biotechnol Bioeng 2009 0.80
53 Hydroxyamide analogs of propofol exhibit state-dependent block of sodium channels in hippocampal neurons: implications for anticonvulsant activity. J Pharmacol Exp Ther 2006 0.79
54 Synthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent. Bioorg Med Chem 2012 0.78
55 Modulation of sodium channel inactivation gating by a novel lactam: implications for seizure suppression in chronic limbic epilepsy. J Pharmacol Exp Ther 2008 0.78
56 Design, synthesis, and evaluation of analogues of 3,3,3-trifluoro-2-hydroxy-2-phenyl-propionamide as orally available general anesthetics. J Med Chem 2003 0.78
57 Reversal of neuropathic pain by alpha-hydroxyphenylamide: a novel sodium channel antagonist. Neuropharmacology 2006 0.78
58 Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95. Mol Pharm 2015 0.78
59 Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α. Mol Endocrinol 2014 0.77
60 Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling. Pharm Res 2012 0.77
61 Effects of a fluorescent Myosin light chain phosphatase inhibitor on prostate cancer cells. Front Oncol 2011 0.77
62 Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma. J Med Chem 2014 0.77
63 Expression of Voltage-Gated Sodium Channel Nav1.8 in Human Prostate Cancer is Associated with High Histological Grade. J Clin Exp Oncol 2012 0.76
64 Synthesis of (S)-jamaicamide C carboxylic acid. Org Lett 2009 0.76
65 Asymmetric synthesis and evaluation of a hydroxyphenylamide voltage-gated sodium channel blocker in human prostate cancer xenografts. Bioorg Med Chem 2011 0.75
66 Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor β2-/- and α7-/- mice. Eur J Pharmacol 2013 0.75
67 Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells. Cancer Biol Ther 2012 0.75
68 In-silico fragment-based identification of novel angiogenesis inhibitors. Bioorg Med Chem Lett 2007 0.75
69 Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation. Bioorg Med Chem 2004 0.75